LOXL2 and pulmonary fibrosis: Indeed, a monoclonal antibody against LOXL2 was reported to ameliorate experimental pulmonary fibrosis [42], and humanized IgG4 monoclonal antibody against LOXL2 is under development as a new antifibrotic treatment [43].